Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications (Q77598543)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

review article

1 reference

title

Ursodeoxycholic acid in cholestasis: potential mechanisms of action and therapeutic applications (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

author name string

U Beuers

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

J L Boyer

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

G Paumgartner

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

language of work or name

English

0 references

publication date

1 December 1998

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

volume

28

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

page(s)

1449-1453

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

6 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Pharmacology of ursodeoxycholic acid, an enterohepatic drug.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Acute effects of ursodeoxycholic and chenodeoxycholic acid on the small intestinal absorption of bile acids

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of the major hydrophobic bile acids in health and in chronic cholestatic liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid administration on bile acid metabolism in patients with early stages of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid-induced changes of plasma and urinary bile acids in patients with primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Cholestasis in Rats induced by Taurolithocholate

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effects of Ursodeoxycholate and cholate feeding on liver disease in FVB mice with a disrupted mdr2 P-glycoprotein gene.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Cirrhosis of the Liver induced in Rabbits by Gastric Instillation of 3-Monohydroxycholanic Acid

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Hepatic injury induced by bile salts: correlation between biochemical and morphological events

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Bile acid-induced liver toxicity: relation to the hydrophobic-hydrophilic balance of bile acids.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Tauroursodeoxycholate prevents taurocholate induced cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholate reduces hepatotoxicity of bile salts in primary human hepatocytes.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Conjugates of ursodeoxycholate protect against cytotoxicity of more hydrophobic bile salts: in vitro studies in rat hepatocytes and human erythrocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Tauroursodeoxycholate prevents taurolithocholate-induced cholestasis and toxicity in rat liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Different protective effects of tauroursodeoxycholate, ursodeoxycholate, and 23-methyl-ursodeoxycholate against taurolithocholate-induced cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Taurine conjugate of ursodeoxycholate plays a major role in the hepatoprotective effect against cholestasis induced by taurochenodeoxycholate in rats

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Homozygous disruption of the murine mdr2 P-glycoprotein gene leads to a complete absence of phospholipid from bile and to liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Molecular aspects of membrane stabilization by ursodeoxycholate [see comment]

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholate conjugates protect against disruption of cholesterol-rich membranes by bile salts.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Kinetics of hepatic bile acid handling in cholestatic liver disease: effect of ursodeoxycholic acid.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. UDCA-PBC Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid in the treatment of primary biliary cirrhosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid for treatment of primary sclerosing cholangitis: a placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Scintigraphic documentation of an improvement in hepatobiliary excretory function after treatment with ursodeoxycholic acid in patients with cystic fibrosis and associated liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

The secretory function of the liver: new aspects of hepatobiliary transport

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Regulation of activity and apical targeting of the Cl-/HCO3- exchanger in rat hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Vesicle targeting to the apical domain regulates bile excretory function in isolated rat hepatocyte couplets.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Role of vesicle-mediated transport pathways in hepatocellular bile secretion

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Newly synthesized hepatocyte plasma membrane proteins are transported in transcytotic vesicles in the bile duct-ligated rat

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Tauroursodeoxycholic acid stimulates hepatocellular exocytosis and mobilizes extracellular Ca++ mechanisms defective in cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Involvement of microtubules in the swelling-induced stimulation of transcellular taurocholate transport in perfused rat liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Mitogen-activated protein kinases mediate the stimulation of bile acid secretion by tauroursodeoxycholate in rat liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

https://api.crossref.org/works/10.1002%2FHEP.510280601

1 reference

7 January 2021

Mechanisms and regulation of bile secretion

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Tauroursodeoxycholic acid inhibits the cytosolic Ca++ increase in human neutrophils stimulated by formyl-methionyl-leucyl-phenylalanine

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effects of bile acids and cholestasis on major histocompatibility complex class I in human and rat hepatocytes

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Prognosis in primary biliary cirrhosis: model for decision making

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Updating prognosis in primary biliary cirrhosis using a time-dependent Cox regression model. PBC1 and PBC2 trial groups

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Effect of ursodeoxycholic acid on liver and bile duct disease in primary sclerosing cholangitis. A 3-year pilot study with a placebo-controlled study period

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Primary sclerosing cholangitis: refinement and validation of survival models

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Natural history and prognostic factors in 305 Swedish patients with primary sclerosing cholangitis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Efficacy of ursodeoxycholic acid treatment and endoscopic dilation of major duct stenoses in primary sclerosing cholangitis. An 8-year prospective study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid in the treatment of cholestasis of pregnancy: a randomized, double-blind study controlled with placebo.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian Group for the Study of Ursodeoxycholic Acid in Cystic Fibrosis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Low-dose versus high-dose ursodeoxycholic acid in cystic fibrosis-related cholestatic liver disease. Results of a randomized study with 1-year follow-up

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid therapy in pediatric patients with progressive familial intrahepatic cholestasis

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid therapy in the treatment of biliary atresia

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid for treatment of cholestasis in children on long-term total parenteral nutrition: a pilot study

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodeoxycholic acid treatment of refractory chronic graft-versus-host disease of the liver

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Failure of ursodeoxycholic acid to prevent acute cellular rejection after liver transplantation

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

The Nordic multicenter double-blind randomized controlled trial of prophylactic ursodeoxycholic acid in liver transplant patients

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

A randomized clinical trial of ursodeoxycholic acid as adjuvant treatment to prevent liver transplant rejection.

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Ursodiol in the long-term treatment of chronic hepatitis: a double-blind multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1002%2FHEP.510280601

7 January 2021

Identifiers

DOI

10.1002/HEP.510280601

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:9828205%20AND%20SRC:MED&resulttype=core&format=json

6 December 2019

1 reference